Original Research

DOI: 10.4244/EIJ-D-24-00037

Treatment extent of femoropopliteal disease and clinical outcomes following endovascular therapy

Yong-Hoon Yoon1, MD, PhD; Jae-Hwan Lee1, MD, PhD; Won-Mook Hwang1, MD; Hyun-Woong Park1, MD, PhD; Jae-Hyung Roh1, MD, PhD; Seung-Jun Lee2, MD, PhD; Young-Guk Ko2, MD, PhD; Chul-Min Ahn2, MD, PhD; Cheol Woong Yu3, MD, PhD; Seung-Whan Lee4, MD, PhD; Young Jin Youn5, MD, PhD; Jong Kwan Park6, MD, PhD; Chang-Hwan Yoon7,8, MD, PhD; Seung-Woon Rha9, MD, PhD; Pil-Ki Min10, MD, PhD; Seung-Hyuk Choi11, MD, PhD; In-Ho Chae7,8, MD, PhD; Donghoon Choi2, MD, PhD

Abstract

BACKGROUND: Endovascular therapy (EVT) has become the preferred treatment modality for femoropopliteal disease. However, there is limited evidence regarding its procedural and clinical outcomes according to the affected area.

AIMS: The aim of this study is to investigate clinical outcomes and device effectiveness according to treatment extent in the superficial femoral artery (SFA), popliteal artery (PA), or both.

METHODS: In this study, we analysed EVT for SFA (2,404 limbs), PA (155 limbs), SFA/PA (383 limbs) using the population in the K-VIS ELLA (Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases) registry. The primary endpoint was target lesion revascularisation (TLR) at 2 years.

RESULTS: The SFA/PA group exhibited a higher prevalence of anatomical complexity, characterised by long lesions, moderate to severe calcification, and total occlusion. The procedures were successful in 97.2% of SFA, 92.9% of PA, and 95.6% of SFA/PA EVTs. The 2-year TLR rates were 21.1%, 18.6%, and 32.7% in the SFA, PA, and SFA/PA groups, respectively. SFA/PA EVT was associated with a significantly increased risk for TLR compared to the SFA group (adjusted hazard ratio [HR] 1.48 [1.09-2.00]; p=0.008) and a trend towards an increased risk compared to the PA group (adjusted HR 1.80 [1.00-3.27]; p=0.052). After overlap weighting, the use of a drug-coated balloon (DCB) was shown to be beneficial, with the lowest TLR rate after SFA and SFA/PA EVT.

CONCLUSIONS: In this large real-world registry, SFA/PA EVT was associated with an increased risk for TLR at 2 years compared to the SFA or PA EVT groups, with favourable outcomes when using a DCB or drug-eluting stent in the SFA/PA EVT group.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 18
Sep 16, 2024
Volume 20 Number 18
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-22-00046 Dec 2, 2022
Drug-coated balloons in the real world: do they hold up?
Secemsky E and Korjian S
free

State-of-the-Art

10.4244/EIJ-D-23-01080 Sep 16, 2024
Drug-eluting devices for lower limb peripheral arterial disease
Gouëffic Y et al
free

CLINICAL RESEARCH

10.4244/EIJ-D-16-00735 Jul 20, 2017
Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis
Cassese S et al
free
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
26

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved